Characterization of Pulmonary Microbiome in Cystic Fibrosis Patients

NCT04735679 | Unknown

• 1 other identifier: RECHMPL21_0053
• Study Type: observational
• Target: 250
• Locations: 1 country
• Sites: 1

Brief Summary

The composition and role of the pulmonary microbiota is not yet well described in cystic fibrosis patients. The objective of our longitudinal follow-up of primary colonised patients is to show the presence of a link between the composition of the microbiota and the effectiveness of antibiotic therapy. All patients followed at the Montpellier CF center will be asked to participate in this cohort. All patients have a regular follow-up every 1 to 6 months and will be asked at each visit to keep their sputum sample in excess of the analyses requested for their follow-up

Conditions

Cystic Fibrosis

Keywords

MICROBIOLOGY; MULTI-OMIC; SPUTUM; PULMONARY MICROBIOTA; CYSTIC FIBROSIS; COHORT; ANTIBIOTHERAPY

Outcome Measures

Primary Outcomes (3)

• to determine a characterisation of the microorganisms of the lung microbiota

  to characterise the microorganisms of the lung microbiota and their interspecific interactions by taxonomic and functional analyses.

  1 day

• to determine a ink between the Composition of the microbiota

  To demonstrate the relationship between the composition of the microbiota and the evolution of the disease Defines the effectiveness of anti-inflammatory biotherapy in patients with cystic fibrosis

  1 day

• to determine a Effectiveness of antibiotic therapy

  To identify abiotic conditions that may contribute to the gap between the efficacy of antibiotics in vitro and in vivo. Show that the microbiota plays a role in the effectiveness of antibiotic treatment.

  1 day

Eligibility Criteria

• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Cystic fibrosis patients

You may qualify if:

• \- Cystic fibrosis patient

You may not qualify if:

• \- Refusal to participate in this research

Sponsors & Collaborators

• University Hospital, Montpellier: lead

Study Sites (1)

Uh Montpellier

Montpellier, 34295, France

RECRUITING

MeSH Terms

Conditions

Cystic Fibrosis

Condition Hierarchy (Ancestors)

Pancreatic Diseases; Digestive System Diseases; Lung Diseases; Respiratory Tract Diseases; Genetic Diseases, Inborn; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Infant, Newborn, Diseases

Study Officials

• Raphael CHIRON, PU-PH

  University Hospitals of Montpellier

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Raphael CHIRON, PU-PH

CONTACT

467336089; r-chiron@chu-montpellier.fr

Alexandre COUDRAT

CONTACT

alexandre.coudrat@outlook.frfr

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 29, 2021
• First Posted: February 3, 2021
• Study Start: January 1, 2021
• Primary Completion: December 1, 2023
• Study Completion: December 31, 2023
• Last Updated: February 5, 2021

Record last verified: 2021-01

Locations

FR (1)